| Date | Title | Description |
| 01.12.2025 | Molecular Partners: Pioneering Targeted Radiopharmaceuticals | 01.12.2025 10:30, Rita Longobardi
Founded in 2004 as a spin-off from the University of Zurich, Molecular Partners, a Roadshow Partner of Venture Leaders Biotech, has spent two decades developing DARPin-based therapeutics designed to address... |
| 31.10.2025 | More than 20 Swiss biotech companies to exhibit at Bio Europe |
Bio-Europe, the leading partnering conference for the global biotechnology industry, is held annually to connect biotech, pharma, investors, and service providers through one-to-one meetings, presentations, and panels. It serves as a leadi... |
| 10.06.2025 | Molecular Partners vor Massenentlassung |
Molecular Partners entwickelt eine neue Klasse von massgeschneiderten Proteinmedikamenten, die sogenannten DARPin-Therapeutika. Das 2004 gegründete Biotech-Unternehmen befindet sich in der klinischen Entwicklungsphase. Um die Effizienz der... |
| 08.11.2024 | Bio-Europe: Switzerland's Biotech Showcase in Stockholm | The heart of Europe beats strong in Stockholm this November. Bio-Europe, the continent's premier partnering event for the life sciences, is back for its 30th edition. This year, it promises to be a melting pot of innovation, collaboration, ... |
| 05.11.2024 | Bio Europe in Stockholm hosts 33 Swiss companies |
Currently in its 30-year-edition, BIO-Europe remains Europe's leading partnering event, for the life sciences ecosystem, providing an exceptional opportunity to explore the latest trends learn and connect with potential partners. The past ... |
| 25.10.2024 | Molecular Partners Announces Pricing of $20 Million Underwritten Offering | ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of cus... |
| 31.05.2024 | Swiss life science startups headed for San Diego |
The BIO International Convention 2024, taking place in San Diego from 3 to 6 June, is the largest global biotechnology event with over 20,000 industry leaders from around the world attending. The target group includes representatives from ... |
| 22.05.2024 | "EMBRACING INTERNATIONAL ALLIANCES" SWISS BIOTECH INNOVATION ON DISPLAY AT THE BIO 2024 INTERNATIONAL CONVENTION IN SAN DIEGO JUNE 3-6, 2024 | ZURICH, May 22, 2024 /PRNewswire/ -- Swiss life science innovation will again be on display at the BIO 2024 convention in San Diego. Switzerland Global Enterprise will present 41 leading Swiss biotech stars at the SWISS BIOTECH pavilion dem... |
| 30.05.2023 | Positive results for Swiss biotechs’ clinical studies | |
| 16.01.2023 | Listed Swiss Biotechs at full throttle | |
| 14.01.2022 | Molecular Partners Reports Disclosure of Major Shareholder as per Swiss Stock Exchange Regulations | ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of cu... |
| 10.01.2022 | Novartis : COVID-19 news feed | Find the latest coronavirus (COVID-19) news from Novartis regarding clinical trials, collaborations, aid contributions, and more.
Jan 10, 2022
Jan 10, 2022 Novartis and Molecular Partners report positive topline data from Phase 2 study for ... |
| 10.01.2022 | Molecular Partners’ COVID-19 drug demonstrates efficacy | |
| 14.12.2021 | Molecular Partners : Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology - Form 6-K | Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology
Collaboration to leverage world class capabilities of Molecular Partners DARPin platform with Novartis' in... |
| 14.12.2021 | Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology | Collaboration to leverage world class capabilities of Molecular Partners DARPin platform with Novartis’ in radioligand therapy to explore the potential for novel targeted therapies for cancer
Novartis will pay $20 million upfront, commercia... |
| 03.12.2021 | Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AML | Research collaboration with leading acute myeloid leukemia (AML) experts,
Professor Ochsenbein and
Professor Riether from the Department of Medical Oncology, Inselspital, Bern University Hospital, Switzerland, to support advancement of drug... |
| 16.11.2021 | Molecular Partners' Covid 19 drug falters in Phase 3 trials | |
| 04.11.2021 | Molecular Partners Announces First Patient Dosed with CD40 Therapeutic Candidate MP0317 in Phase 1 Clinical Trial | Second immuno-oncology DARPin candidate to enter the clinic; combines immune stimulation with validated tumor-localizing technology
Preclinical data support potential to deliver tumor-localized immune activation while avoiding systemic toxi... |
| 28.10.2021 | Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology Momentum - Form 6-K | Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology Momentum
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcem... |
| 28.10.2021 | Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology Momentum | ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of cust... |
| 21.10.2021 | Novartis : COVID-19 news feed | Find the latest coronavirus (COVID-19) news from Novartis regarding clinical trials, collaborations, aid contributions, and more.
Oct 21, 2021
Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-... |
| 27.08.2021 | Molecular Partners : Reports Corporate Highlights and Key Financials for H1 2021 (Form 6-K) | Molecular Partners Reports Corporate Highlights and Key Financials for H1 2021
-- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage t... |
| 26.08.2021 | Molecular Partners : Reports Corporate Highlights and Key Financials for H1 2021 | -- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3
Research & Development:
Initiated two global Phas... |
| 21.06.2021 | Encouraging progress of COVID-19 solutions from Switzerland | |
| 21.06.2021 | Encouraging progress of COVID-19 solutions from Switzerland | CHF 1 million for a next-generation vaccine
The University Hospital Basel (USB), the University of Basel and the Swiss Tropical and Public Health Institute (Swiss TPH) are entering into a research collaboration with the startup company Rock... |
| 16.06.2021 | MOLECULAR PARTNERS AG
Molecular Partners : Announces Pricing of Initial Public Offering of American Depositary Shares in the United States | Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States
PDF
Zurich-Schlieren, Switzerland, June 16, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company develop... |
| 13.06.2021 | MOLECULAR PARTNERS AG
Molecular Partners : Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep | Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep
PDF
Global Phase 3 trial designed to investigate safety and efficacy of ensovibep in hospitalized adults with ... |
| 09.06.2021 | MOLECULAR PARTNERS AG
Molecular Partners : Announces Launch of American Depositary Shares (ADS) Offering in the United States | Molecular Partners Announces Launch of American Depositary Shares (ADS) Offering in the United States
PDF
Zurich-Schlieren, Switzerland, June 9, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company developing a new clas... |
| 06.04.2021 | MOLECULAR PARTNERS AG
Molecular Partners : Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients | Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
PDF
First study of ensovibep in patients with symptomatic COVID-19 disease
Designed to evaluate dynamics of viral clearance, phar... |
| 15.03.2021 | With hopes for antibodies waning, the NIH will test Novartis partner's novel antiviral in hospitalized Covid-19 patients | After a slew of failures, the NIH’s ACTIV-3 trial for hospitalized Covid-19 patients has earned its reputation as a graveyard for big-name antibodies. Now, with its options running out, the NIH is turning to a Novartis-b... |
| 25.11.2020 | Development milestones for startups with Corona solutions | |
| 25.11.2020 | Development milestones for startups with Corona solutions | Ender Diagnostics is based in Bern with a US subsidiary with offices in New Jersey and Miami. The startup is developing molecular diagnostic test kits for the rapid and reliable detection of SARS-CoV-2. Its testing kits, ender LAB and ender... |
| 28.10.2020 | Novartis joins Molecular Partners as investor and collaboration partner | |
| 28.10.2020 | Novartis joins Molecular Partners as investor and collaboration partner | The DARPin therapeutics program developed by Molecular Partners is a new class of custom-built protein drugs comprising of two multi-targeted direct-acting antiviral therapeutic candidates, MP0420 and MP0423, designed for potential use agai... |
| 11.08.2020 | Swiss Government to buy anti-COVID-19 drugs from Molecular Partners | Molecular Partners AG, a clinical-stage biotech company that is developing a new class of custom-built proteins known as DARPin therapeutics, today announced the reservation by the Swiss Federal Office of Public Health: Bundesamt für Gesund... |
| 11.08.2020 | Swiss Government to buy anti-COVID-19 drugs from Molecular Partners | |
| 07.07.2020 | Molecular Partners raises CHF80 million via private placement | Ten days after the announcement of a major setback regarding the marketing approval of its most advanced molecule, Molecular Partners AG announces the successful completion of a private placement. The company has successfully placed 5,528,0... |
| 07.07.2020 | Molecular Partners raises CHF80 million via private placement | |
| 26.06.2020 | Major setback for Molecular Partners | Molecular Partners and Allergan, an AbbVie Company today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter to the Biologics License Application (BLA) for Abicipar pegol, a novel, investigationa... |
| 26.06.2020 | Major setback for Molecular Partners | |
| 19.05.2020 | Eleven Swiss start-ups on the virtual BIO Digital stage | |
| 19.05.2020 | Eleven Swiss start-ups on the virtual BIO Digital stage | BIO International Convention has transformed into BIO Digital to bring together players in the biotech industry to exchange ideas even in times when it is impossible to gather physically. From 8 - 12 June, more than 2300 companies from all ... |
| 19.07.2019 | Medicxi closes a €400M Fund to back biopharma entrepreneurs | |
| 19.07.2018 | Positive phase 3 results for Molecular Partner’s most advanced molecule | |
| 21.06.2018 | AdoRx raises $10M for adenosine program in cancer; Molecular Partners poaches Regeneron, recruiting Pamela Trail as CSO | → A day after iTeos raised $75 million to accelerate its research plans on an adenosine program for cancer, a new rival has sprung up in Scotland. AdoRx has raised $10 million from Epidarex Capital and CRT Pioneer Fund, af... |
| 03.01.2018 | Two biotech startups receive milestone payments | |
| 19.05.2017 | Peer Review: Former FDA Commish Califf will split his time between Verily and Duke | → After a little over a year and a half at Alphabet’s Verily, neuroscientist Dr. Thomas Insel is joining the mysterious company’s exodus of talent and calling it quits. Insel ran the National Institute of Mental H... |
| 10.12.2015 | Molecular Partners among the best newcomers at European stock exchanges | |
| 09.11.2015 | Molecular Partner’s DARPins may help reshape anticancer treatment | |
| 07.10.2015 | Molecular Partners honoured for its pioneering technology | |
| 22.07.2015 | Allergan reinforces commitment to Molecular Partners | |
| 07.07.2015 | Molecular Partners receives USD 15 million milestone payment | |
| 09.12.2014 | Milestone payment from Janssen for Molecular Partners | |
| 08.10.2014 | Molecular Partners: First trading day expected for 22 October 2014 | |
| 23.09.2014 | Molecular Partners launches IPO on SIX Swiss Exchange | |
| 22.09.2014 | Molecular Partners one of the most promising biotech companies worldwide | |
| 03.07.2014 | Molecular Partners: Phase III development of a DARPin on the horizon | |
| 04.12.2013 | Molecular Partners enters into another billion dollar alliance | |
| 17.01.2013 | Molecular Partners publishes encouraging results of a clinical study | |
| 12.11.2012 | Molecular Partners and Boehringer have entered into a strategic manufacturing collaboration | Under the terms of the agreement, Boehringer Ingelheim will be responsible for the generation of the E. coli production strains and the manufacture of tox and clinical stage material for multiple DARPin products supplying Molecular Partners... |
| 21.08.2012 | Molecular Partners signs Billion Dollar Contract with Allergan | |
| 27.06.2012 | Climeworks gewinnt den Preis der Preisträger bei den de Vigier Awards | |
| 19.06.2012 | Index Ventures raises EUR350m for new early stage technology fund | |
| 05.04.2012 | Compound from Molecular Partners is safe and well tolerated | Normal 0 21 false false false DE-CH X-NONE X-NONE |
| 08.12.2011 | Molecular Partners enters into a Strategic Collaboration with Janssen Biotech | |
| 15.12.2009 | Molecular Partners Secures CHF 46 Million in Series B Financing Led by Essex Woodlands Health Ventures | - |
| 15.12.2009 | Switzerland, Molecular Partners Secures CHF46M in Series B Financing | Molecular Partners AG, a Zurich, Switzerland-based developer of protein therapeutics, has announced the closing of its CHF 46 million (€30m, $45m) Series B equity investment round.
The round was led by new investor Essex Woodlands Health Ve... |
| 16.01.2008 | Life sciences briefing: Wednesday, Jan. 16, 2008 | TODAY’S HEADLINES:
Drug-screening tool maker IonGate Bio raises €4.6M (release)
Protein-drug maker Molecular Partners gets $5M up front in Centocor deal (PDF release)
ProtaGen takes in €1M for protein biochips (PDF release)
China’s Sundia M... |
| 15.08.2007 | Life sciences briefing: Wednesday, Aug. 15, 2007 | (UPDATED at 5:55pm PT: See below.)
Featured companies: Sierra Surgical Technologies, HerbalScience Nutraceuticals, Topigen Pharmaceuticals, EKR Therapeutics, Molecular Partners, Celsense, Glucose Sensing Technologies, Falcon Genomics, Water... |
